

# OPTIMA HEALTH PLAN

## PHARMACY/MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

Directions: *The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-723-2094. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.*

**Drug Requested:** Immune Globulin Intravenous (IVIG) (immunodeficiency)  
{Primary Immune Deficiency}

**DRUG INFORMATION:** Complete all information below. If incomplete, authorization process will be delayed.

**Circle applicable J Code:** J1459 / J1556 / J1561 / J1566 / J1568 / J1569 / J1572

**Drug Name/Form:** \_\_\_\_\_ **Strength/Month:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_ **Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code:** \_\_\_\_\_

Continuation of Therapy for Primary Immune Deficiency:  Yes  No

*Medical notes and Labs values must be submitted to support each line checked on this request.*

**CLINICAL DIAGNOSIS:** Check ALL applicable boxes below. Authorization process will be delayed if not completed.

- |   |   |
|---|---|
| <input type="checkbox"/> Severe combined immunodeficiency                   | <input type="checkbox"/> CD40 ligand deficiency (X-linked hyper-IgM syndrome)       |
| <input type="checkbox"/> X-linked or autosomal recessive agammaglobulinemia | <input type="checkbox"/> Nuclear factor of $\kappa$ B essential modifier deficiency |
| <input type="checkbox"/> Common variable immunodeficiency                   | <input type="checkbox"/> Ataxia-telangiectasia                                      |
| <input type="checkbox"/> Wiskott-Aldrich syndrome                           | <input type="checkbox"/> DiGeorge Syndrome  |

*The following diagnoses MUST meet ALL of the following additional criteria:*

- |   |  |
|---|--|
| <input type="checkbox"/> IgG subclass deficiency                    | <input type="checkbox"/> Significant and clearly documented infectious morbidity such as recurrent pneumonia, frequent episodes of documented bacterial sinusitis (not isolated chronic sinusitis) |
| <input type="checkbox"/> IgA deficiency                             | <input type="checkbox"/> Allergy, anatomic defects, and other causes of increased infection susceptibility have been aggressively treated  |
| <input type="checkbox"/> Specific antibody deficiency               | <input type="checkbox"/> Failure of antimicrobial and anti-inflammatory therapies  |
| <input type="checkbox"/> Transient hypogammaglobulinemia of infancy |  |
| <input type="checkbox"/> Unspecified hypogammaglobulinemia          |  |

**CLINICAL CRITERIA:** Check one of the following below. The criteria MUST be met to qualify.

- IgG level <500 mg/dL (must submit copy of lab results from past 6 months) **AND** medical documentation showing recurrent infections and a concurrent diagnosis as above

**AND**

- Documented abnormal response to streptococcal vaccines (i.e., 4 fold increase in titers) to protein and polysaccharide antigens. (must submit copy of documentation of administration as well as streptococcal vaccine laboratory titer results at least 4 weeks after administration)

**OR**

(continued on next page)

**FOR CONTINUATION OF THERAPY**

- Documented history of humoral or combined immunodeficiency with claims for IVIG (*must submit documentation showing paid claims for IVIG*)

**Medication being provided by (check applicable box below):**

- Physician's office

**OR**

- Specialty Pharmacy:
- PropriumRx

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

\*Approved by Pharmacy and Therapeutics Committee: 7/16/2015  
REVISED/UPDATED: 8/26/2015; 1/29/2016; 8/18/2016; 9/22/2016; 12/11/2016; 7/27/2017;